4D Molecular Therapeutics Q3 2026 Results: Net Loss of $78.1M, Loss Widens
4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.
- Key figure
- Net loss $78.1M